In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL). The company’s shares opened today at $140.09.
According to TipRanks.com, Olson is a 1-star analyst with an average return of -2.3% and a 45.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Conatus Pharmaceuticals, Enanta Pharmaceuticals, and Spero Therapeutics Inc.
Madrigal Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $168.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $325.98 and a one-year low of $91.56. Currently, Madrigal Pharmaceuticals Inc has an average volume of 242.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
